Cancer Sequencing Tools

SeraCare’s clinical genomics technologies enable the promise of precision medicine by helping scientists and clinicians build and implement better assays.

Tools for NGS-based tumor profiling assays

SeraCare has the widest selection of variants and variant types, flexible patient-like sample formats (both formalin-fixed, paraffin-embedded FFPE and plasma reference standards), easy-to-use purified nucleic acid formats, and precise control over individual mutation frequencies.

Comprehensive solutions for every stage:

NGS-Based Cancer Assay Development                                                             

Assay Development

Assay Validation

Laboratory QC


Abundant, consistent, and stable materials with valuable mutations


Readily available, patient-like materials to evaluate your entire workflow


Reliable materials that are easy to use, and effective data management tools. 


Standards for Cancer Sequencing of Solid Tumors  


Are you looking for:

  • Rare, actionable variants to challenge your assay’s and pipeline’s ability for detection
  • Variants at or near your assay’s limit of detection (LOD)
  • A variety of formats from full-process FFPE sections to purified DNA as daily run standards     

Solid tumor cancer sequencing standards

Rare, actionable variants to challenge your clinical oncology test

SeraCare in consultation with clinical laboratory experts has designed actionable, challenging variants including single nucleotide variants (SNVs), insertion-deletion mutations (indels), structural variants (SVs), and RNA fusion transcripts.

Flexible minor variant allele frequency at or near LOD

Using a biosynthetic approach, these variants can be flexibly formulated at virtually any allele frequency desired, whether slightly above, slightly below, or well above your assay’s LOD. 

Both FFPE and purified DNA formats

Formalin-fixed, paraffin-embedded (FFPE) cell lines enables Seraseq products to serve as full-process reference materials, monitoring the entire workflow. Purified Mutation DNA Mixes are also available for daily, routine use that avoid the DNA purification step.

Economical, precise, consistent reference material

Multiplexing variants (including SNVs, indels and SVs) in a single sample economically examines 40 variants simultaneously, while digital PCR ensures accurate quantitation. Developed in cGMP-compliant, ISO 13485 certified facilities, Seraseq NGS reference materials provide a consistent source of reference standards.

Format Product Material Number

 

FFPE

 

Seraseq™ FFPE Tumor Fusion RNA Reference Material v2


0710 - 0129
FFPE Seraseq™ FFPE Tumor Fusion RNA Reference Material v1 0710 - 0010
FFPE Seraseq™ FFPE Tumor KRAS Reference Material Kit 0710 - 0117
Purified RNA Seraseq™ Fusion RNA Mix v2 0710 - 0127
Purified DNA Seraseq™ Tumor Mutation DNA Mix v2 AF4 LC 0710 - 0070
Purified DNA Seraseq™ Tumor Mutation DNA Mix v2 AF7 LC 0710 - 0072
Purified DNA Seraseq™ Tumor Mutation DNA Mix v2 AF10 LC 0710 - 0074
Purified DNA Seraseq™ Tri-Level Tumor Mutation DNA Mix v2 LC 0710 - 0076
Purified DNA Seraseq™ Tri-Level Tumor Mutation DNA Mix v2 HC 0710 - 0077
Purified DNA Seraseq™ Tumor Mutation DNA Mix v2 AF10 HC 0710 - 0094
Purified DNA Seraseq™ Tumor Mutation DNA Mix v2 AF7 HC 0710 - 0095
Purified DNA Seraseq™ Tumor Mutation DNA Mix v2 AF4 HC 0710 - 0096

For research use only. Not for use in diagnostic procedures.

/globalassets/images/figures-and-illustrations/dna_mutation4-404616-edited.jpg

Check out our VariantFlex™ Library Custom Services

Click Here

 

Standards for Cancer Sequencing of Liquid Biopsies

Are you looking for:

  • Rare, actionable variants that will challenge your assay’s ability for detection
  • Variants at a full range of your assay’s LOD, from 5% down to 0.12%
  • Full-process, stabilized, and size-appropriate DNA fragments in synthetic plasma

Liquid biopsy circulating tumor DNA cancer sequencing standards

Rare, actionable variants to challenge your ctDNA test

SeraCare in consultation with clinical laboratory experts has designed actionable, challenging variants including single nucleotide variants (SNVs) and insertion-deletion mutations (indels).

Flexible minor variant allele frequency at or near LOD

These variants can be flexibly formulated at virtually any allele frequency desired, whether slightly above, slightly below, or well above your assay’s LOD.

Both synthetic plasma and purified DNA formats

A proprietary stabilization method and plasma-like Seracon Matribase enable Seraseq products to serve as full-process ctDNA reference materials, monitoring the entire workflow. Purified Mutation DNA Mixes are also available that avoid the DNA purification step to assist with assay development and optimization.

Economical, precise, consistent reference material

Multiplexing variants (including SNVs and indels) in a single sample economically examines 9 variants simultaneously, while digital PCR ensures accurate quantitation. Developed in a GMP-compliant, ISO 13485 certified facilities, Seraseq NGS reference materials provide a consistent source of reference standards. 

Format Product Material Number
     
Patient-like, synthetic plasma Seraseq™ Circulating Tumor DNA-I Reference Material (AF5) 0710 - 0012
Patient-like, synthetic plasma Seraseq™ Circulating Tumor DNA-I Reference Material (AF1.2) 0710 - 0014
Patient-like, synthetic plasma Seraseq™ Circulating Tumor DNA-I Reference Material (AF0.6) 0710 - 0015
Patient-like, synthetic plasma Seraseq™ Circulating Tumor DNA-I Reference Material (AF0.1) 0710 - 0016
Patient-like, synthetic plasma Seraseq™ Circulating Tumor DNA-I Reference Material (WT) 0710 - 0017
Purified CtDNA Seraseq™ Circulating Tumor DNA-I Mutation Mix Kit (AF5-WT) 0710 - 0018

For research use only: Not for use in diagnostic procedures